Curated News
By: NewsRamp Editorial Staff
June 11, 2026
VERAXA Biotech Completes Business Combination, Begins Trading on Nasdaq
TLDR
- VERAXA Biotech's BiTAC platform targets cancer cells selectively, offering a competitive edge in precision oncology.
- VERAXA completed a business combination with Voyager Acquisition Corp and secured up to $77.5M to advance BiTAC programs.
- VERAXA's therapies aim to selectively target cancer cells while sparing healthy tissue, improving patient quality of life.
- VERAXA's BiTAC platform was developed from scientific breakthroughs at the European Molecular Biology Laboratory.
Impact - Why it Matters
This news matters because it signals the public market entry of a biotech firm with a promising platform for next-generation cancer therapies. The BiTAC platform's ability to selectively target cancer cells could lead to more effective and less toxic treatments, addressing a critical need in oncology. The substantial financing secured also indicates strong investor confidence, which may accelerate the development of these therapies toward clinical trials and eventual patient access.
Summary
VERAXA Biotech (NASDAQ: VRXA) has officially completed its business combination with Voyager Acquisition Corp. (NASDAQ: VACH), marking the formation of VERAXA Biotech AG. The newly formed entity will begin trading on the Nasdaq Capital Market under the ticker symbol VRXA, with warrants trading under VRXAW. This milestone brings together VERAXA's innovative pipeline of bispecific T-cell engagers and antibody-drug conjugates (ADCs) built on its proprietary BiTAC platform, designed to selectively target cancer cells while minimizing harm to healthy tissue.
The company has secured significant financing to advance its programs, including a $27.5 million senior secured note and a securities purchase agreement of up to $50 million. These funds are expected to propel the BiTAC-TCE and BiTAC-ADC candidates toward clinical development. Notably, VERAXA recently presented preclinical data at the AACR Annual Meeting 2026, showcasing favorable efficacy and safety profiles for its lead BiTAC-TCE candidate. For full details, visit the press release at https://ibn.fm/ka00j.
VERAXA Biotech AG is built on foundational scientific breakthroughs from the European Molecular Biology Laboratory, emphasizing rigorous quality-by-design principles. Voyager Acquisition Corp., a special purpose acquisition company, brings expertise in healthcare innovation and scaling companies. Investors can find the latest updates in the company’s newsroom at http://ibn.fm/VRXA. BioMedWire, a specialized communications platform under the Dynamic Brand Portfolio @ IBN, continues to provide coverage of this development.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, VERAXA Biotech Completes Business Combination, Begins Trading on Nasdaq
